Myriad Genetics Stock
Price
Target price
€17.70
€17.70
3.510%
0.6
3.510%
€23.22
23.04.24 / Stuttgart Stock Exchange
WKN: 897518 / Symbol: MYGN / Name: Myriad Genetics / Stock / Healthcare Equipment & Supplies / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Myriad Genetics Stock
Myriad Genetics dominated the market today, gaining €0.60 (3.510%).
Currently there is a rather positive sentiment for Myriad Genetics with 5 Buy predictions and 2 Sell predictions.
As a result the target price of 23 € shows a positive potential of 29.94% compared to the current price of 17.7 € for Myriad Genetics.
Pros and Cons of Myriad Genetics in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
B****
Cons
?
C******** o* t** e**********
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Myriad Genetics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Myriad Genetics | 3.510% | -3.933% | -16.990% | -14.070% | -3.390% | -28.780% | -40.697% |
| Integer Hldg | - | -2.679% | 1.869% | 49.315% | 22.472% | 42.484% | 72.687% |
| Healthequity Inc. | -1.970% | 1.333% | 3.401% | 46.154% | 27.731% | 25.371% | - |
| Omnicell Inc. | 0.770% | 3.175% | 1.563% | -51.402% | -25.714% | -76.991% | -59.464% |
Comments
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $28.00 to $31.00. They now have a "buy" rating on the stock.
Show more
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) is now covered by analysts at Guggenheim. They set a "buy" rating and a $23.00 price target on the stock.
Show more
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $28.00 price target on the stock.
Show more
Ratings data for MYGN provided by MarketBeat
